secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0001493152-24-012774
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaPro subsidiary reports net loss of $246K; going concern doubt flagged
-------------------------------------------------------------------------

- BriaPro incurred net loss of $245,960 for six months ended Jan 31, 2024 (no prior-year comparison).
- Assets of $207,432 (mainly intangible patents) offset by $250,678 current liabilities; shareholders' deficit of $231,367.
- Going concern note: 'significant doubt' about ability to continue as pre-clinical stage company needs further financing.
- Due to parent BriaCell $196,549 under transition services agreement; warrant liability of $188,121 recorded.
- Operating loss of $257,057; R&D expenses $168,536 and G&A $88,494 for the six-month period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315224012774/0001493152-24-012774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315224012774/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-012774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer